
JCR and Alexion deal boosts AAV-based gene therapy
JCR Pharmaceuticals and Alexion, AstraZeneca Rare Disease, have entered into a license agreement for JCR’s JUST-AAV capsids to develop genomic medicines. JUST-AAV encompasses a range of vector types optimised for various target tissues—including liver-sparing, muscle-targeting, and brain-targeting variants—to expand the potential of AAV-based gene therapy. Under the terms of the… Read More
